The triglyceride-glucose index predicts 1-year major adverse cardiovascular events in end-stage renal disease patients with coronary artery disease.
Journal Information
Full Title: Cardiovasc Diabetol
Abbreviation: Cardiovasc Diabetol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Vascular Diseases
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateThe study was conducted under the Declaration of Helsinki and received approval from the China-Japan Friendship Hospital Ethics Committee (No. 2020-112-K71), with a waiver of informed consent. Consent for publicationNot applicable. Competing interestsThere are no conflicts of interest. Competing interests There are no conflicts of interest."
"Funding This work was supported by the National High Level Hospital Clinical Research Funding (2022-NHLHCRF-YSPY-01), Science Foundation of China-Japan Friendship Hospital (No. 2020-HX-40), National Key Clinical Specialty Construction Project (2020-QTL-009), and Capital’s Founds for Health Improvement and Research (No. 2022-1-4062)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025